Ariel A Schulman1, Christina Sze1, Efrat Tsivian1, Rajan T Gupta1,2,3, Judd W Moul1,2, Thomas J Polascik4,5. 1. Division of Urology, Department of Surgery, Duke University Medical Center, Box 2804, Yellow Zone, Durham, NC, 27710, USA. 2. Duke Cancer Institute, Durham, USA. 3. Department of Radiology, Duke University Medical Center, Durham, NC, USA. 4. Division of Urology, Department of Surgery, Duke University Medical Center, Box 2804, Yellow Zone, Durham, NC, 27710, USA. thomas.polascik@duke.edu. 5. Duke Cancer Institute, Durham, USA. thomas.polascik@duke.edu.
Abstract
PURPOSE OF REVIEW: Growing research supports the use of multiparametric magnetic resonance imaging (mpMRI) for the evaluation of localized prostate cancer (PCa). We highlight contemporary evidence supporting its use in active surveillance (AS). RECENT FINDINGS: The emerging approach to localized PCa favors risk-adapted screening, image-guided biopsies, and selective therapeutic interventions. mpMRI is increasingly critical to achieve each of these aims. Early evidence suggests a value of mpMRI before initial biopsy to guide fusion targeting and to rule out non-organ confined disease as well as in the initiation and serial monitoring of men on AS. There remain concerns regarding understaging cancer with mpMRI and the standardization of expertise beyond the most experienced centers. mpMRI is emerging as a critical decision point for staging localized PCa and guiding AS strategies. While there is increasing enthusiasm, the optimal clinical scenario and sequencing remains to be defined.
PURPOSE OF REVIEW: Growing research supports the use of multiparametric magnetic resonance imaging (mpMRI) for the evaluation of localized prostate cancer (PCa). We highlight contemporary evidence supporting its use in active surveillance (AS). RECENT FINDINGS: The emerging approach to localized PCa favors risk-adapted screening, image-guided biopsies, and selective therapeutic interventions. mpMRI is increasingly critical to achieve each of these aims. Early evidence suggests a value of mpMRI before initial biopsy to guide fusion targeting and to rule out non-organ confined disease as well as in the initiation and serial monitoring of men on AS. There remain concerns regarding understaging cancer with mpMRI and the standardization of expertise beyond the most experienced centers. mpMRI is emerging as a critical decision point for staging localized PCa and guiding AS strategies. While there is increasing enthusiasm, the optimal clinical scenario and sequencing remains to be defined.
Entities:
Keywords:
Active surveillance; Diagnostic imaging; Multiparametric magnetic resonance imaging; Prostate cancer; Risk stratification
Authors: E David Crawford; David M Albala; James S Wysocki; Herbert Lepor; Ashley E Ross; Steven E Finkelstein; Thomas Keane; Stephen Freedland; Richard Harris; Neal D Shore; Charles J Ryan Journal: Rev Urol Date: 2016
Authors: M Minhaj Siddiqui; Soroush Rais-Bahrami; Baris Turkbey; Arvin K George; Jason Rothwax; Nabeel Shakir; Chinonyerem Okoro; Dima Raskolnikov; Howard L Parnes; W Marston Linehan; Maria J Merino; Richard M Simon; Peter L Choyke; Bradford J Wood; Peter A Pinto Journal: JAMA Date: 2015-01-27 Impact factor: 56.272
Authors: Ardeshir R Rastinehad; Steven F Abboud; Arvin K George; Thomas P Frye; Richard Ho; Raju Chelluri; Michele Fascelli; Joanna Shih; Robert Villani; Eran Ben-Levi; Oksana Yaskiv; Baris Turkbey; Peter L Choyke; Maria J Merino; Bradford J Wood; Peter A Pinto Journal: J Urol Date: 2016-01-23 Impact factor: 7.450
Authors: Arnoud W Postema; Maudy C W Gayet; Ruud J G van Sloun; Rogier R Wildeboer; Christophe K Mannaerts; C Dilara Savci-Heijink; Stefan G Schalk; Amir Kajtazovic; Henk van der Poel; Peter F A Mulders; Harrie P Beerlage; Massimo Mischi; Hessel Wijkstra Journal: World J Urol Date: 2020-02-20 Impact factor: 4.226
Authors: Marco Roscigno; Armando Stabile; Giovanni Lughezzani; Pietro Pepe; Lucio Dell'Atti; Angelo Naselli; Richard Naspro; Maria Nicolai; Giovanni La Croce; Aljoulani Muhannad; Giovanna Perugini; Giorgio Guazzoni; Francesco Montorsi; Luca Balzarini; Sandro Sironi; Luigi F Da Pozzo Journal: Prostate Int Date: 2020-05-28